{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:16:33Z","timestamp":1777418193505,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019397","name":"Actuate Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007174","name":"Array BioPharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center","doi-asserted-by":"publisher","award":["P30 CA 008748"],"award-info":[{"award-number":["P30 CA 008748"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019145","name":"Boston Biomedical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016751","name":"Parexel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100477","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T19:18:35Z","timestamp":1653938315000},"page":"100477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC"],"prefix":"10.1016","volume":"7","author":[{"given":"S.","family":"Kopetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.K.","family":"Guren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-T.","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garcia-Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100477_bib1","author":"Macrae"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2022.100477_bib4","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1186\/1471-2482-13-S2-S15","article-title":"Health related quality of life in colorectal cancer patients: state of the art","volume":"13","author":"Marventano","year":"2013","journal-title":"BMC Surg"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12955-018-0934-7","article-title":"Quality of life and physical activity in long-term (\u22655 years post-diagnosis) colorectal cancer survivors - systematic review","volume":"16","author":"Eyl","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2022.100477_bib8","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100477_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: a systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100477_bib10","first-page":"266","article-title":"Factors affecting quality of life in cancer patients undergoing chemotherapy","volume":"11","author":"Heydarnejad","year":"2011","journal-title":"Afr Health Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1188\/09.CJON.54-64","article-title":"Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes","volume":"13","author":"Hawkins","year":"2009","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100477_bib12","first-page":"e1312","article-title":"Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital","volume":"4","author":"Ramasubbu","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100477_bib13","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.3390\/ijerph17196938","article-title":"Quality of life of cancer patients treated with chemotherapy","volume":"17","author":"Lewandowska","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100477_bib14","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1200\/JCO.2004.02.018","article-title":"Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study","volume":"22","author":"Arndt","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100477_bib15","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.esmoop.2021.100328","article-title":"Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study","volume":"6","author":"Tabernero","year":"2021","journal-title":"ESMO Open"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100477_bib16","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/cncr.29415","article-title":"How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium","volume":"121","author":"Kenzik","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1186\/s12885-018-5075-1","article-title":"Health-related quality of life in long-term survivors of colorectal cancer and its association with all-cause mortality: a German cohort study","volume":"18","author":"Ratjen","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100477_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100477_bib19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100477_bib20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0959-8049(02)00098-9","article-title":"Baseline quality of life predicts survival in patients with advanced colorectal cancer","volume":"38","author":"Maisey","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100477_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7525-9-62","article-title":"Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer?","volume":"9","author":"Braun","year":"2011","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100477_bib22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/annonc\/mdx191","article-title":"How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials","volume":"28","author":"Bonnetain","year":"2017","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2022.100477_bib24","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100477_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019117","article-title":"Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol","volume":"8","author":"Musoro","year":"2018","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100477_bib27","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/codi.15295","article-title":"Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy","volume":"22","author":"Musoro","year":"2020","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.esmoop.2022.100477_bib29","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100477_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1008821826499","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument","volume":"8","author":"Ward","year":"1999","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100477_bib35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/curroncol28030194","article-title":"The Screening and COnsensus Based on Practices and Evidence (SCOPE) program-results of a survey on daily practice patterns for patients with mCRC","volume":"28","author":"Prager","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2022.100477_bib36","unstructured":"World Health Organization. Medicines Reimbursement Policies in Europe (2018); 2018. Available at https:\/\/www.euro.who.int\/en\/publications\/abstracts\/medicines-reimbursement-policies-in-europe. Accessed February 3, 2022."},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2022.100477_bib37","article-title":"How we treat metastatic colorectal cancer","volume":"4","author":"De Falco","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib38","first-page":"e117","article-title":"Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice","volume":"18","author":"Bekaii-Saab","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100477_bib39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12955-020-01580-0","article-title":"Chemotherapy use and quality of life in cancer patients at the end of life: an integrative review","volume":"18","author":"Akhlaghi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100477_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157067","article-title":"Time to definitive health-related quality of life score deterioration in patients with resectable metastatic colorectal cancer treated with FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI: the MIROX randomized phase III trial","volume":"11","author":"Hamidou","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100477_bib41","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2008.19.6048","article-title":"Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial","volume":"27","author":"Au","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100477_bib42","first-page":"e29","article-title":"Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab plus chemotherapy","volume":"16","author":"Yamaguchi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100477_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2012.08.023","article-title":"Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin","volume":"49","author":"Lang","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100477_bib44","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.2147\/CMAR.S186042","article-title":"The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer","volume":"11","author":"Battaglin","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2022.100477_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-12-438","article-title":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study","volume":"12","author":"Thaler","year":"2012","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100477_bib46","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1634\/theoncologist.2008-0003","article-title":"Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer","volume":"13","author":"Kabbinavar","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100477_bib47","first-page":"183","article-title":"Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)","volume":"18","author":"Riechelmann","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100477_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdy526","article-title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients","volume":"30","author":"Shitara","year":"2019","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:11Z","timestamp":1761856031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2059702922000953"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100477","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Pfizer and The Author(s). Published by Elsevier Ltd. On behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100477"}}